Clinical Trials Browser

Phase 2 × Melanoma × tislelizumab × Clear all

NCT04924413 2024-07-03

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Phase 2 Terminated

Melanoma

NCT05104801 2021-11-04

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Phase 2 Unknown

Melanoma